In addition, and considering the presence of RET rearrangements already identified in 1–3% of non-small cell lung cancers [12], and the poor overall survival already demonstrated in advanced PTC patients harboring such translocations [2], we re-highlight the need of using highly specific small-molecule RET inhibitors [13] in patients with RET-rearranged advanced TCs. The gene discussed is RET; the disease is non-small cell lung carcinoma.